Hong Kong IPO Prospectus for Zelgen Biopharmaceutical Lapses

Stock News

Jun 22

An IPO prospectus for a Hong Kong listing submitted by Suzhou Zelgen Biopharmaceutical Co., Ltd. has lapsed. The document, which was filed on December 19, 2025, became invalid on June 19, 2026, after the standard six-month period. At the time of the initial filing, China International Capital Corporation Limited was the sole sponsor.

According to the prospectus, Suzhou Zelgen Biopharmaceutical Co., Ltd. (SSE: 688266) is a comprehensive biopharmaceutical company. It focuses on the discovery, development, and commercialization of innovative small-molecule and biologic therapies, with a strategic emphasis on oncology, autoimmune diseases, and hemostasis/hematological disorders.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1117535956"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1117535956\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1117535956?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-22 11:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1117535956","market":"us","top_or_hot":-1,"title":"Hong Kong IPO Prospectus for Zelgen Biopharmaceutical Lapses","media":"Stock News","content":"<p>An IPO prospectus for a Hong Kong listing submitted by Suzhou Zelgen Biopharmaceutical Co., Ltd. has lapsed. The document, which was filed on December 19, 2025, became invalid on June 19, 2026, after the standard six-month period. At the time of the initial filing, China International Capital Corporation Limited was the sole sponsor.<br><br>According to the prospectus, <b>Suzhou Zelgen Biopharmaceutical Co., Ltd.</b> (<b>SSE: 688266</b>) is a comprehensive biopharmaceutical company. It focuses on the discovery, development, and commercialization of innovative small-molecule and biologic therapies, with a strategic emphasis on oncology, autoimmune diseases, and hemostasis/hematological disorders.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hong Kong IPO Prospectus for Zelgen Biopharmaceutical Lapses</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHong Kong IPO Prospectus for Zelgen Biopharmaceutical Lapses\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-06-22 11:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>An IPO prospectus for a Hong Kong listing submitted by Suzhou Zelgen Biopharmaceutical Co., Ltd. has lapsed. The document, which was filed on December 19, 2025, became invalid on June 19, 2026, after the standard six-month period. At the time of the initial filing, China International Capital Corporation Limited was the sole sponsor.<br><br>According to the prospectus, <b>Suzhou Zelgen Biopharmaceutical Co., Ltd.</b> (<b>SSE: 688266</b>) is a comprehensive biopharmaceutical company. It focuses on the discovery, development, and commercialization of innovative small-molecule and biologic therapies, with a strategic emphasis on oncology, autoimmune diseases, and hemostasis/hematological disorders.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IPOS","symbol_name":"Renaissance International IPO ETF","start_time":0,"source_url":"","article_id":"1117535956","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1117535956","pubTimestamp":1782097579,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"An IPO prospectus for a Hong Kong listing submitted by Suzhou Zelgen Biopharmaceutical Co., Ltd. has lapsed. The document, which was filed on December 19, 2025, became invalid on June 19, 2026, after...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688266":"泽璟制药-U","IPOS":"Renaissance International IPO ETF","VXUS":"国际股票ETF-Vanguard","BK0239":"医药制造","BK1191":"制药","01477":"欧康维视生物-B","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK1574":"生物医药B类股"},"translate_title":"泽璟生物制药香港IPO招股说明书失效","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688266":1,"VXUS":1,"IPOS":1,"01477":1},"content_text":"An IPO prospectus for a Hong Kong listing submitted by Suzhou Zelgen Biopharmaceutical Co., Ltd. has lapsed. The document, which was filed on December 19, 2025, became invalid on June 19, 2026, after the standard six-month period. At the time of the initial filing, China International Capital Corporation Limited was the sole sponsor.According to the prospectus, Suzhou Zelgen Biopharmaceutical Co., Ltd. (SSE: 688266) is a comprehensive biopharmaceutical company. It focuses on the discovery, development, and commercialization of innovative small-molecule and biologic therapies, with a strategic emphasis on oncology, autoimmune diseases, and hemostasis/hematological disorders.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}